Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

K. Zaman; D. A. Sack; M. Yunus; S. E. Arifeen; G. Podder; T. Azim; S. Luby; R. F. Breiman; K. Neuzil; S. K. Datta; A. Delem; P. V. Suryakiran; H. L. Bock

doi:10.1016/j.vaccine.2008.12.059

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

K. Zaman, D. A. Sack, M. Yunus, S. E. Arifeen, G. Podder, T. Azim, S. Luby, R. F. Breiman, K. Neuzil, S. K. Datta, A. Delem, P. V. Suryakiran, H. L. Bock

Research output: Contribution to journal › Article › peer-review

Abstract

Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.

Original language	English (US)
Pages (from-to)	1333-1339
Number of pages	7
Journal	Vaccine
Volume	27
Issue number	9
DOIs	https://doi.org/10.1016/j.vaccine.2008.12.059
State	Published - Feb 25 2009
Externally published	Yes

Keywords

Gastrointestinal disease
Oral poliovirus
Rotavirus
Vaccine

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2008.12.059

Fingerprint Dive into the research topics of 'Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age'. Together they form a unique fingerprint.

Cite this

Zaman, K., Sack, D. A., Yunus, M., Arifeen, S. E., Podder, G., Azim, T., Luby, S., Breiman, R. F., Neuzil, K., Datta, S. K., Delem, A., Suryakiran, P. V., & Bock, H. L. (2009). Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine, 27(9), 1333-1339. https://doi.org/10.1016/j.vaccine.2008.12.059

Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. / Zaman, K.; Sack, D. A.; Yunus, M.; Arifeen, S. E.; Podder, G.; Azim, T.; Luby, S.; Breiman, R. F.; Neuzil, K.; Datta, S. K.; Delem, A.; Suryakiran, P. V.; Bock, H. L.

In: Vaccine, Vol. 27, No. 9, 25.02.2009, p. 1333-1339.

Research output: Contribution to journal › Article › peer-review

Zaman, K, Sack, DA, Yunus, M, Arifeen, SE, Podder, G, Azim, T, Luby, S, Breiman, RF, Neuzil, K, Datta, SK, Delem, A, Suryakiran, PV & Bock, HL 2009, 'Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age', Vaccine, vol. 27, no. 9, pp. 1333-1339. https://doi.org/10.1016/j.vaccine.2008.12.059

Zaman, K. ; Sack, D. A. ; Yunus, M. ; Arifeen, S. E. ; Podder, G. ; Azim, T. ; Luby, S. ; Breiman, R. F. ; Neuzil, K. ; Datta, S. K. ; Delem, A. ; Suryakiran, P. V. ; Bock, H. L. / Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. In: Vaccine. 2009 ; Vol. 27, No. 9. pp. 1333-1339.

@article{51cd493f4d2c429fa829dd3a60b2b826,

title = "Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age",

abstract = "Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix{\texttrademark}) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.",

keywords = "Gastrointestinal disease, Oral poliovirus, Rotavirus, Vaccine",

author = "K. Zaman and Sack, {D. A.} and M. Yunus and Arifeen, {S. E.} and G. Podder and T. Azim and S. Luby and Breiman, {R. F.} and K. Neuzil and Datta, {S. K.} and A. Delem and Suryakiran, {P. V.} and Bock, {H. L.}",

year = "2009",

month = feb,

day = "25",

doi = "10.1016/j.vaccine.2008.12.059",

language = "English (US)",

volume = "27",

pages = "1333--1339",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

AU - Zaman, K.

AU - Sack, D. A.

AU - Yunus, M.

AU - Arifeen, S. E.

AU - Podder, G.

AU - Azim, T.

AU - Luby, S.

AU - Breiman, R. F.

AU - Neuzil, K.

AU - Datta, S. K.

AU - Delem, A.

AU - Suryakiran, P. V.

AU - Bock, H. L.

PY - 2009/2/25

Y1 - 2009/2/25

N2 - Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.

AB - Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.

KW - Gastrointestinal disease

KW - Oral poliovirus

KW - Rotavirus

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=59849113985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59849113985&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.12.059

DO - 10.1016/j.vaccine.2008.12.059

M3 - Article

C2 - 19162114

AN - SCOPUS:59849113985

VL - 27

SP - 1333

EP - 1339

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -